Xenognosin B

Xenognosin B

SCHEMBL72611

COc1ccc(-c2coc3cc(O)ccc3c2=O)c(O)c1

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.83
ALDH1A1 P00352 10/20 0.83
HPGD P15428 9/20 0.83
HSD17B10 Q99714 9/20 0.83
CYP3A4 P08684 5/20 0.83
MAPT P10636 7/20 0.76
SMN1; SMN2 Q16637 5/20 0.76
TP53 P04637 4/20 0.76
MAOA P21397 3/20 0.76
MAOB P27338 3/20 0.76
MEN1 O00255 2/20 0.76
KMT2A Q03164 2/20 0.76
CYP2D6 P10635 2/20 0.76
CYP2C9 P11712 2/20 0.76
CYP2C19 P33261 2/20 0.76
HDAC6 Q9UBN7 2/20 0.76
BCL2 P10415 1/20 0.76
IL2 P60568 1/20 0.76
CYP1B1 Q16678 1/20 0.76
PPARG P37231 2/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Xenognosin B SCHEMBL30851576 1.00 KDM4E (0.83) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL2971118 0.94 XDH (0.76) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL9992779 0.92 KDM4E (0.76) KDM4EALDH1A1HPGDHSD17B10CYP3A4
2'-Methoxyformonetin SCHEMBL29777010 0.91 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10CYP3A4
2'-Methoxyformonetin SCHEMBL234355 0.91 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL72610 0.87 KDM4E (0.72) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL31134786 0.87 KDM4E (0.72) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL29737520 0.87 KDM4E (0.72) KDM4EALDH1A1HPGDHSD17B10CYP3A4
Formononetin SCHEMBL15271536 0.86 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10CYP3A4
Formononetin SCHEMBL29361145 0.86 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051551-A1 IMPROVED POLYMER COMPOSITES WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2025-02-13 US claimed
US-20120003273-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) 2012-01-05 US claimed
EP-2346844-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS Council Of Scientific & Industrial Research (IN) 2011-07-27 EP claimed
WO-2010052734-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2010-05-14 WO claimed
US-20020177527-A1 Methods for the identification of inhibitors of 2'-hydroxyisoflavone reductase expression or activity in plants ICORIA, INC. 2002-11-28 US claimed
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities THE BROAD INSTITUTE, INC. (US) 2026-03-17 US disclosed
US-20250376656-A1 MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-12-11 US disclosed
WO-2025049925-A2 LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES POSEIDA THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
US-20250051551-A1 IMPROVED POLYMER COMPOSITES WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2025-02-13 US disclosed
US-12163004-B2 Polymer composites WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2024-12-10 US disclosed
US-20240355451-A1 METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY NESTLE SA (CH) 2024-10-24 US disclosed
EP-4391834-A1 METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY Société des Produits Nestlé S.A. (CH) 2024-07-03 EP disclosed
EP-1263937-A2 RECOMBINANT PINORESINOL/LARICIRESINOL REDUCTASE, RECOMBINANT DIRIGENT PROTEIN, AND METHODS OF USE Washington State University Research Foundation (US) 2002-12-11 EP disclosed
US-20020177527-A1 Methods for the identification of inhibitors of 2'-hydroxyisoflavone reductase expression or activity in plants ICORIA, INC. 2002-11-28 US disclosed
WO-2002092776-A2 METHODS FOR THE INDENTIFICATION OF INHIBITORS OF 2-HYDROXYISOFLAVONE REDUCTASE EXPRESSION OR ACTIVITY IN PLANTS BAYER CROPSCIENCE AG (DE) 2002-11-21 WO disclosed
WO-2001049833-A2 RECOMBINANT PINORESINOL/LARICIRESINOL REDUCTASE, RECOMBINANT DIRIGENT PROTEIN, AND METHODS OF USE WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) 2001-07-12 WO disclosed
US-6210942-B1 USEFUL AS POLYMERASE CHAIN REACTION PRIMERS, OR AS PROBES FOR PINORESINOL/LARICIRESINOL REDUCTASE GENES, DIRIGENT PROTEIN GENES, OR RELATED GENES WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION 2001-04-03 US disclosed
US-5750399-A CONTROL TRANSCRIPTION IN PLANTS THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) 1998-05-12 US disclosed
EP-0792356-A1 ISOFLAVONE REDUCTASE PROMOTER The Samuel Roberts Noble Foundation, Inc. (US) 1997-09-03 EP disclosed
WO-1996015239-A2 ISOFLAVONE REDUCTASE PROMOTER THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) 1996-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120003273-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS AKR1C3, AKR1C4, SLC10A1 KDM4E 2194/4885ALDH1A1 1999/4885HPGD 1138/4885
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities STUB1, SAMM50, CD14 KDM4E 2737/4885ALDH1A1 1629/4885HPGD 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.